Insulin-like growth factor II (IGF-II) is over-expressed in more than 90% of ACCs [24], [41], [42] and represents the major marker that allows the distinction between benign adenomas and malignant tumours [24], [25]. This evidence concerns the gene IGF2 and adenoma.